Key result
Among 47 LVAD centers worldwide, pharmacologic and nicotine replacement therapies were the most common smoking cessation strategies, though only about half perceived them as effective.
Why the study?
Tobacco smoking causes significant morbidity in patients with durable LVADs, but the ability of LVAD centers to implement successful tobacco cessation programs remains uncertain.
What are the tobacco smoking cessation strategies utilized by left ventricular assist device centers and what is their perceived effectiveness?
Cross-Sectional (n=47)
Yes
What are the tobacco smoking cessation strategies utilized by left ventricular assist device centers and what is their perceived effectiveness?
Despite common use of pharmacologic and nicotine replacement therapies for smoking cessation in LVAD patients, many centers perceive them as ineffective, and a significant minority believe smoking should preclude destination therapy, challenging current guidelines.
Answers are grounded in this paper and cite their sources.
Variable perceived efficacy of common cessation therapies in LVAD centers; leaves open standardized protocols and prospective trials.
BACKGROUND: Tobacco smoking is a significant source of morbidity in patients with a durable left ventricular assist device. While various cessation strategies have been investigated, the ability of ventricular assist device centers to implement a successful tobacco cessation program remains uncertain. We explored various cessation strategies employed by ventricular assist device centers and assessed perspectives of their effectiveness, as well as institutional investment in these programs. METHODS: and distributed worldwide. We investigated (1) programmatic strategies utilized for smoking cessation, (2) the respondent's perspective on the effectiveness of these strategies, (3) the structure with which these therapies are administered, and (4) overall organizational support for these treatments. RESULTS: A total of 47 centers worldwide completed the survey. The most common methods of tobacco cessation were pharmacologic and nicotine replacement therapy (78% and 66%). However, only about half (47% and 50%, respectively) of the centers indicated that these strategies were effective. When asked whether a respondent's center perceives that tobacco smoking should be a deciding factor in destination therapy evaluations, nearly a third (15, 32%) responded in the affirmative. CONCLUSION: While significant overlap exists among centers regarding treatments used for smoking cessation with left ventricular assist device patients, the most common treatments are not thought to be effective. While the current recommendations require tobacco smoking cessation in only bridge-to-transplant patients and not destination therapy patients, a number of centers disagree with the national guidelines and believe smoking should be prohibited in both populations.
No takes yet. Share an insight, caveat, or question.
Combs et al. (2020) conducted a cross-sectional in Tobacco smoking in left ventricular assist device patients (n=47). Tobacco smoking cessation strategies was evaluated on Utilization and perceived effectiveness of smoking cessation strategies. Among 47 LVAD centers worldwide, pharmacologic and nicotine replacement therapies were the most common smoking cessation strategies, though only about half perceived them as effective.
Synapse has enriched 10 related papers. Consider them for comparative context: